<DOC>
	<DOC>NCT01452659</DOC>
	<brief_summary>The purpose of this study is to determine the efficacy and safety of TAK-385, once daily (QD), for 12 weeks in women with uterine fibroids.</brief_summary>
	<brief_title>Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids</brief_title>
	<detailed_description>This study is a Phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled for evaluation of the efficacy and safety of TAK-385 10, 20, and 40 mg (p.o.) following once daily administration for 12 weeks in women with uterine fibroids.</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>1. The participant has been diagnosed with uterine fibroids and has never received surgical treatment for the myoma. 2. The participant is a premenopausal woman. 3. The participant has one or more measurable noncalcified myomas confirmed by transvaginal sonography. 4. The participant has experienced regular menstrual cycles 5. The participant is diagnosed as menorrhagia 1. Participants with a screening Hb &lt;8 g/dL 2. Participants with a previous or current history of blood disorders 3. Participants with a known history of severe hypersensitivity or severe allergy to sanitary goods 4. Participants with lower abdominal pain due to irritable bowel syndrome or severe interstitial cystitis 5. Participants with a previous or current history of thyroid dysfunction 6. Participants with a previous or current history of pelvic inflammatory disease 7. Participants with a positive PAP smear test result 8. Participants with a history of panhysterectomy or bilateral oophorectomy 9. Participants judged by investigator to have marked abnormal uterine bleeding or anovulatory bleeding 10. Participants with a previous or current history of a malignant tumor 11. Participants who have been treated with any of the following drugs: anticoagulant drug, antiplatelet drug, tranexamic acid, selective estrogen receptor modulator (SERM), activated vitamin D, other vitamin D, calcitonin, ipriflavone, steroid hormone, vitamin K, teriparatide, or denosumab 12. Participants who have been treated with any of the following drugs: oral contraceptive and sex hormone preparation, gonadotropinreleasing hormone (GnRH) analogue, dienogest, danazol, or aromatase inhibitor 13. Participants who have been treated with a bisphosphonate preparation 14. Participants with a previous or current history of severe hypersensitivity or severe allergy to drugs 15. Participants with nondiagnosable abnormal genital bleeding 16. Participants with a previous or current history of osteoporosis, bone mass loss, or other metabolic bone diseases 17. Participants with clinically significant cardiovascular disease or uncontrollable hypertension 18. Participants judged by investigator to be inappropriate to participate in this study based on the 12lead electrocardiogram (ECG) findings 19. Participants with active liver disease or jaundice, or with alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin &gt; 1.5 times the upper limit of normal (ULN)</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>